title: [Role and indication of GLP-1 analogues in the treatment of type 2 diabetes].
abstract: Available therapies for type 2 diabetes are not always satisfactory because they do not address the problems of overweight/obesity and the progressive deterioration of cell function. GLP-1 analogues or agonists of the GLP-1 receptor are a new therapeutic option which offer promises; they indeed improve glycemic control, decrease weight by 2-3 kg/year and may stabilize or improve cell function by favoring cell proliferation and inhibiting apoptosis. Their use in patients who are not sufficiently controlled by metformin and sulfonylurea compares favourably to insulin treatment.
authors: Service d'endocrinologie, diabètologie et nutrition, HUG, 1211 Genève 14.
authors: Jacques
authors: J
authors: Philippe
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide